- Home
- CRMD vs FDMT Comparison
CRMD vs FDMT Comparison
Compare CRMD & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | FDMT |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.9M | 513.6M |
| IPO Year | 2009 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CRMD | FDMT |
|---|---|---|
| Price | $6.34 | $8.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $14.67 | ★ $32.40 |
| AVG Volume (30 Days) | ★ 1.4M | 629.5K |
| Earning Date | 06-05-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $311,709,000.00 | $37,000.00 |
| Revenue This Year | $1.10 | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $5.60 | $2.24 |
| 52 Week High | $17.43 | $12.34 |
Technical Indicators
Market Signals| Indicator | CRMD | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 42.97 |
| Support Level | $6.13 | $8.15 |
| Resistance Level | $7.44 | $8.80 |
| Average True Range (ATR) | 0.29 | 0.50 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 18.42 | 11.61 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.